Document is current
Any future updates will be listed below
-
Authors
Zhuang, Kaiting
Wang, Wenjuan
Zheng, Xumin
Guo, Xinru
Xu, Cheng
Ren, Xuejing
Shen, Wanjun
Han, Qiuxia
Feng, Zhe
Chen, Xiangmei
Cai, Guangyan https://orcid.org/0000-0001-8586-6353
-
Funding
Funding for this research was provided by:
Natural Science Foundation of China (82170686)
National Key Research and Development Program of China (2022YFC3602900)
Grant for GYC (22KJLJ001)
- License Information
-
More Information
Article History
Received: 29 March 2024
Accepted: 2 November 2024
First Online: 19 November 2024
Declarations
:
: hUC-MSCs used in this study were donated by Vcanbio Cell & Gene Engineering Corp. Ltd, which had confimmed that there was initial ethical approval for collection of human cells, and that informed consent was duly signed by the donors. The animal experiments were conducted in line with the ARRIVE guidelines 2.0. All animal experiments were performed under ethical supervision and approved by the Institutional Animal Care and Use Committee of the Chinese PLA General Hospital in 2022 (Title research: Study on stem cell therapy for acute kidney injury. No. 2022-X18-39). This ethics approval also permitted performing experiments using the aforementioned hUC-MSCs.
: Not applicable.
: The authors declare that they have no competing interests.
